INMED PHARMACEUTICALS INC. Derivative Liability, Noncurrent
INMED PHARMACEUTICALS INC. (INM) had Derivative Liability, Noncurrent of $1.76 million as of 2020-12-31, per its 10-Q filed 2021-02-11.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2021-02-11
- 2020-12-31: Derivative Liability, Noncurrent $1.76M.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2020-12-31 | $1.76M 10-Q · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |